These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6886033)

  • 1. Serum calcium and magnesium levels in chronic schizophrenics.
    Athanassenas G; Papadopoulos E; Kourkoubas A; Tsitourides S; Gabriel J; Hoïdas S; Frangos E
    J Clin Psychopharmacol; 1983 Aug; 3(4):212-6. PubMed ID: 6886033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment.
    Alexander PE; Van Kammen DP; Bunney WE
    Br J Psychiatry; 1978 Aug; 133():143-9. PubMed ID: 354732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms.
    Alexander PE; van Kammen DP; Bunney WE
    Arch Gen Psychiatry; 1979 Nov; 36(12):1372-7. PubMed ID: 496555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie R; Mackie M; Morrison D; Kidd J
    Br J Psychiatry; 1982 Mar; 140():280-6. PubMed ID: 7093596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors determining patient tenure on a 3-year double-blind investigation of pimozide versus fluphenazine HCl.
    Abuzzahab FS; Zimmermann RL
    Adv Biochem Psychopharmacol; 1980; 24():547-50. PubMed ID: 7405675
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical trial of loxapine succinate in the treatment of 30 cases of psychotic states].
    Escande M; Granier F; Gardes JP; Boscredon J; Concina M
    Ann Med Psychol (Paris); 1983 Mar; 141(3):309-22. PubMed ID: 6357022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Loxapine succinate: a new neuroleptic].
    Cottereau MJ; Poirier MF; Lôo H; Deniker P
    Encephale; 1979; 5(3):251-67. PubMed ID: 39739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe electrolyte disorders following cardiac surgery: a prospective controlled observational study.
    Polderman KH; Girbes AR
    Crit Care; 2004 Dec; 8(6):R459-66. PubMed ID: 15566592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting therapy of schizophrenia.
    Rapisarda V; Bonomo V; Parisi R
    Adv Biochem Psychopharmacol; 1985; 40():25-8. PubMed ID: 4025038
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroleptic-induced extrapyramidal symptoms and serum calcium levels. Results of a pilot study.
    Kuny S; Binswanger U
    Neuropsychobiology; 1989; 21(2):67-70. PubMed ID: 2575718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of schizophrenic psychoses with Lyorodin].
    Schulz HD; Kluge HH; Korda W; Kube B
    Psychiatr Neurol Med Psychol (Leipz); 1977 Jun; 29(6):360-6. PubMed ID: 918199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of changes in levels of calcium, phosphate and magnesium during hemodialysis on autonomic system reactivity as measured by heart rate variability analysis].
    Buda S; Stompór T; Sułowicz W; Kopeć J; Szymczakiewicz-Multanowska A; Janion M
    Przegl Lek; 2000; 57(6):340-5. PubMed ID: 11107869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
    Ritsner M; Gibel A; Ram E; Maayan R; Weizman A
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.